Halton Region Public Health: Office of the Medical Officer of Health
Quick facts
- Pneu-C-20 pediatric eligibility expansion:
- As of June 20, 2025, the Ministry of Health has expanded publicly funded eligibility for pneumococcal 20-valent conjugate vaccine (Pneu-C-20) to include high-risk children.
- Effective immediately, children aged 6 weeks to 17 years who are at high-risk for invasive pneumococcal disease (IPD) and who have completed the Pneu-C-13 series are eligible for one additional dose of Pneu-C-20.
- Pneu-C-20 provides broader protection by covering 7 additional serotypes not included in Pneu-C-13.
- COVID-19 vaccine reminders:
- The spring 2025 COVID-19 vaccine campaign has now ended. Individuals who did not receive a spring dose should now wait for the Fall 2025 campaign.
- High-risk individuals may still receive a spring dose until August 31, at the clinical discretion of their healthcare provider.
- Note: Vaccinating now may impact timing for the fall dose.
Key messages for healthcare providers
- Assess eligibility for Pneu-C-20 (external PDF) in pediatric populations with medical conditions that increase risk for IPD.
- Pneu-C-20 should be administered:
- at least 8 weeks after last dose of Pneu-C-13; or
- at least 1 year after a dose of Pneu-P-23.
- Children who have already received Pneu-C-20 do not require any further doses.
- Use clinical judgment when deciding whether to offer a spring COVID-19 dose to high-risk individuals between now and August 31.